Noninferior efficacy seen for three all-oral regimens compared with standard therapy in intention-to-treat, per-protocol populations
THURSDAY, Feb. 6, 2025 (HealthDay News) — Three all-oral shortened regimens have noninferior efficacy compared with standard therapy for fluoroquinolone-susceptible, rifampin-resistant tuberculosis, according to a study published in the Jan. 30 issue of the New England Journal of Medicine.
Lorenzo Guglielmetti, M.D., Ph.D., from Médecins Sans Frontières in Paris, and colleagues conducted a phase 3, multinational, noninferiority trial to compare standard therapy for treatment of fluoroquinolone-susceptible, rifampin-resistant tuberculosis to five nine-month oral regimens, including combinations of bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C), and pyrazinamide (Z). A total of 754 participants were randomly assigned to one of five combinations or standard therapy; 699 were included in the modified intention-to-treat analysis and 562 were included in the per-protocol analysis. The primary end point was a favorable outcome at week 73, defined by two negative sputum culture results or favorable bacteriologic, clinical, and radiologic evolution. The noninferiority margin was −12 percentage points.
The researchers found that 80.7 percent of the patients in the standard-therapy group had favorable outcomes in the modified intention-to-treat analysis. In the modified intention-to-treat population, the risk difference between standard therapy and each of the four new regimens was noninferior: 9.8, 8.3, 4.6, and 2.5 percentage points for BCLLfxZ, BLMZ, BDLLfxZ, and DCMZ, respectively. In the per-protocol population, the differences were similar, apart from DCMZ, which was not noninferior. Across the regimens, the proportion of participants with grade 3 or higher adverse events was similar.
“The results of this trial support the noninferior efficacy of three all-oral shortened regimens for the treatment of rifampin-resistant tuberculosis,” the authors write.
Two authors disclosed ties to the biopharmaceutical industry.
CHEST Issues Guidelines for Management of Adult Bronchiectasis 
Globally, Youths Not Eating Enough Healthy, Plant-Based Foods 
Antibiotic Prescribing >95 Percent for Uncomplicated Diverticulitis .jpg)
Bypassing the Closest Surgical Site for Urgent Care Tied to Worse Outcomes 
Full, Limited Functional Endoscopic Sinus Surgery Beneficial in Rhinosinusitis With Nasal Polyps .jpg)
Warning Symptoms, Clinical History Can Predict Sudden Cardiac Arrest 
Randomized Trial of Early Vitrectomy Feasible for Postoperative Endophthalmitis 
Protocol IDs Patients Who Can Be Treated While Seated in the ED 
